Ben-Shoshan Moshe, Akin Cem, Cook Victoria E, Khalaf Roy, Freigeh George
Division of Allergy, Immunology&Dermatology, Department of Pediatrics, Montreal Children's Hospital, Montreal QC, Canada.
Department of Medicine, Division of Allergy and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
J Allergy Clin Immunol Pract. 2025 Aug 27. doi: 10.1016/j.jaip.2025.08.019.
Idiopathic anaphylaxis (IA) refers to recurrent, life-threatening hypersensitivity reactions without identifiable triggers, representing a diagnostic and therapeutic challenge. We describe a 17-year-old girl presenting with recurrent episodes of flushing, pruritus, and respiratory symptoms, without consistent allergen exposure or cofactor involvement. Evaluation revealed elevated acute tryptase levels with a normal baseline, negative skin testing, and negative alpha-gal and KIT mutation analysis. The patient improved on daily cetirizine with no further reactions. IA remains a diagnosis of exclusion, requiring careful consideration of IgE-mediated allergies, cofactor-dependent anaphylaxis, clonal mast cell disorders, and systemic mimics such as neuroendocrine tumors or vasovagal syncope. We summarize current evidence on IA pathogenesis, epidemiology, differential diagnosis, and management. While antihistamines and corticosteroids are commonly used prophylactically, emerging data suggest anti-IgE therapy with omalizumab may offer benefit in refractory cases. Diagnostic workup should include serum tryptase measurement, trigger identification, and consideration of underlying mast cell disorders. Future research is needed to clarify the natural history, standardize diagnostic pathways, and evaluate long-term treatment strategies for this heterogeneous condition. CASE DESCRIPTION: A 17-year-old girl presented to the emergency department (ED) with a two-hour history of flushing, pruritus, and wheezing. The symptoms began after eating dinner, which included shepherd's pie and macadamia nuts, foods she had previously tolerated. There were no preceding exposures to medications, alcohol, or insect stings, and she did not engage in exercise prior to symptom onset. She reported three additional similar episodes. These were not consistently associated with eating, and there were no common foods or additives identified between episodes. There was no history of tick bite. There was no correlation between reactions and stage of her menstrual cycle. She did not have a personal or family history of atopy (atopic dermatitis, allergic rhinitis, asthma, IgE-mediated food allergy) or anaphylaxis. There was no history of spontaneous or inducible urticaria. She did not have a history of spontaneous flushing, pruritus, abdominal pain, diarrhea, presyncopal or syncopal episodes. She did not have a history of bony pain or fractures. At the time of the medical assessment in the ED, the patient's examination was notable for facial erythema and diffuse hives. Respiratory symptoms had resolved by the time of assessment. There were no cutaneous lesions suggestive of cutaneous mastocytosis. (Figure 1) The examination was otherwise unremarkable. She was given 2 generation antihistamines, and symptoms gradually resolved over several hours. The serum tryptase drawn two hours following symptom initiation was 17.2 mcg/L. A repeat level five days later was 3.2 mcg/L. During a follow up visit three months after ED presentation, skin prick testing (SPT) was negative to a variety of food and inhalant allergens including macadamia nut, wheat and beef. Serum IgE testing to galactose-alpha-1,3-galactose (alpha-gal) was negative, and qPCR analysis for the KIT D816V mutation in peripheral blood was negative. The patient was prescribed prophylactic cetirizine (20 mg daily) for three months, during which she experienced no further reactions. Given the clinical presentation, absence of identifiable triggers and the tryptase levels obtained at the ED and five days later, the patient was diagnosed with idiopathic anaphylaxis (IA).
特发性过敏反应(IA)是指反复发生的、危及生命的超敏反应,且无明确的触发因素,这是一个诊断和治疗上的挑战。我们描述了一名17岁女孩,她反复出现潮红、瘙痒和呼吸道症状,没有持续的过敏原暴露或辅助因素参与。评估显示急性类胰蛋白酶水平升高但基线正常,皮肤试验阴性,α-半乳糖和KIT突变分析阴性。患者在每日服用西替利嗪后病情好转,未再出现反应。IA仍然是一种排除性诊断,需要仔细考虑IgE介导的过敏反应、辅助因子依赖性过敏反应、克隆性肥大细胞疾病以及系统性模仿疾病,如神经内分泌肿瘤或血管迷走性晕厥。我们总结了目前关于IA发病机制、流行病学、鉴别诊断和管理的证据。虽然抗组胺药和皮质类固醇常用于预防性治疗,但新出现的数据表明,使用奥马珠单抗进行抗IgE治疗可能对难治性病例有益。诊断检查应包括血清类胰蛋白酶测量、触发因素识别以及对潜在肥大细胞疾病的考虑。需要进一步的研究来阐明这种异质性疾病的自然史、规范诊断途径并评估长期治疗策略。病例描述:一名17岁女孩因两小时的潮红、瘙痒和喘息症状就诊于急诊科。症状在晚餐后开始,晚餐包括牧羊人派和澳洲坚果,这些食物她以前都能耐受。之前没有接触过药物、酒精或昆虫叮咬,症状发作前也没有进行过运动。她报告还有另外三次类似发作。这些发作并不总是与进食有关,发作之间没有发现常见的食物或添加剂。没有蜱虫叮咬史。反应与她的月经周期阶段没有相关性。她没有特应性疾病(特应性皮炎、过敏性鼻炎、哮喘、IgE介导食物过敏)或过敏反应的个人或家族史。没有自发性或诱发性荨麻疹病史。她没有自发性潮红、瘙痒、腹痛、腹泻、晕厥前期或晕厥发作的病史。没有骨痛或骨折病史。在急诊科进行医学评估时,患者的检查以面部红斑和弥漫性荨麻疹为显著特征。评估时呼吸道症状已经缓解。没有提示皮肤肥大细胞增多症的皮肤病变。(图1)其他检查无异常。她接受了第二代抗组胺药治疗,症状在数小时内逐渐缓解。症状开始两小时后抽取的血清类胰蛋白酶水平为17.2 mcg/L。五天后复查水平为3.2 mcg/L。在急诊科就诊三个月后的随访中,皮肤点刺试验(SPT)对多种食物和吸入性过敏原,包括澳洲坚果、小麦和牛肉均为阴性。针对半乳糖-α-1,3-半乳糖(α-半乳糖)的血清IgE检测为阴性,外周血KIT D816V突变的qPCR分析为阴性。患者被处方预防性服用西替利嗪(每日20 mg)三个月,在此期间她没有再出现反应。鉴于临床表现、无明确的触发因素以及在急诊科和五天后测得的类胰蛋白酶水平,该患者被诊断为特发性过敏反应(IA)。